BiomX Secures $3.0 Million Private Placement to Advance Bacteriophage Therapies for Bacterial Infections
核心洞察
BiomX Inc. (搜索) announced a $3.0 million private placement financing through Series Y Convertible Preferred Stock and warrants to support its bacteriophage therapy programs.
The funding will specifically support assessment of BX011 (搜索), a bacteriophage treatment targeting Staphylococcus aureus infections associated with diabetic foot infections (搜索).
The Series Y Convertible Preferred Stock carries a 15% annual dividend rate and one-year maturity, with warrants exercisable at $2.00 per share over five years.
BiomX Inc. (搜索), a clinical-stage company developing bacteriophage therapies, announced December 29, 2025, that it has secured $3.0 million in gross proceeds through a private investment in public equity financing. The Israeli-based company will use the funding to advance its bacteriophage programs targeting specific pathogenic bacteria, with particular focus on BX011 (搜索) for Staphylococcus aureus infections associated with diabetic foot infections (搜索).
Financing Structure and Terms
The private placement involves the issuance of Series Y Convertible Preferred Stock with a stated value of $1,000 per share, alongside warrants with an aggregate stated value of up to $3.3 million. Each share of preferred stock will accrue dividends at 15% per annum, payable quarterly, with a one-year maturity from the closing date.
The preferred stock will be convertible into common stock shares, subject to limitations outlined in the definitive agreements and potential stockholder approval requirements under NYSE American rules. Additionally, BiomX will issue warrants to acquire up to 3,300,000 shares of common stock, with a five-year term and an exercise price of $2.00 per share.
H.C. Wainwright & Co. (搜索) served as the exclusive placement agent for the transaction, which is expected to close on December 30, 2025, pending satisfaction of customary closing conditions.
Strategic Focus on Bacteriophage Development
BiomX specializes in developing natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for treating chronic diseases (搜索) with substantial unmet medical needs. The company applies its proprietary BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against validated bacterial targets.
The net proceeds from this financing will support the company's assessment of opportunities across its bacteriophage programs, including the continued development of BX011 (搜索). This treatment candidate targets Staphylococcus aureus infections specifically associated with diabetic foot infections (搜索), representing a significant unmet medical need in diabetes care.
Regulatory and Development Pathway
The securities sold in the private placement have not been registered under the Securities Act of 1933 and were offered under exemptions from registration requirements. BiomX has committed to filing a registration statement with the Securities and Exchange Commission to register the resale of common stock shares issuable upon conversion of the preferred stock and exercise of the warrants.
The funding will also provide operational flexibility as BiomX continues evaluating strategic alternatives while advancing its clinical programs. The company's approach to bacteriophage therapy represents an innovative strategy for addressing bacterial infections (搜索), particularly in cases where traditional antibiotic treatments may be limited or ineffective.
Clinical Development Pipeline
BiomX's development strategy centers on discovering and validating proprietary bacterial targets, then applying its BOLT platform to create customized phage compositions. This personalized approach to bacteriophage therapy aims to provide targeted treatment options for patients with chronic bacterial infections (搜索).
The focus on diabetic foot infections (搜索) through BX011 (搜索) addresses a critical medical need, as these infections can lead to serious complications including amputation in diabetic patients. The company's bacteriophage approach offers a potential alternative to conventional antibiotic treatments, which may face challenges with antibiotic-resistant bacterial strains.